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The human apoA1 gene was expressed in E. coli by in-frame fusion to a modified /%galactosidase g ne pre- 
sent in plasmid pUR291. The fused /?-galactosidase-apoA1 gene product was expressed at a high level and 
was recognized by an anti-human apoA1 antiserum. Besides the fused protein, at least one degradation 
product having an M, similar to that of /?-galactosidase was present in high amounts in bacterial extracts. 
These results and those of a pulse-chase xperiment indicate that degradation took place only in the apoA1 
moiety of the chimeric protein. 
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1. INTRODUCTION 
The protein components of plasma lipoproteins 
play a central role in the regulation of lipid 
metabolism. Apolipoprotein AI (apoA1) is the ma- 
jor polypeptide of human plasma high density 
lipoproteins (HDL), which seem to be inversely 
correlated with the incidence of coronary heart 
disease (CHD) [ 1,2]. This correlation suggests that 
the protective effect of HDL is related to their 
capacity to act as an acceptor of tissue cholesterol, 
including that which accumulates in the arterial 
wall. High concentrations of HDL in plasma might 
influence CHD by retarding atherogenesis or pro- 
moting regression, although the molecular basis 
for this contention has not yet been elucidated. 
Evidence for the involvement of HDL in reverse 
cholesterol transport was reported recently [3]. 
Production of apoA1 in microorganisms would 
facilitate the study of the relationships between 
structure and biological activity of lipid-carrier 
proteins and their mutants. 
2. MATERIALS AND METHODS 
Cultures of E. coli K12 JMlOl [4] and E. coli 
MC 1061 [S] were in LB medium with 50pg/ml 
ampicillin when needed (LA medium) or in M9 
minimal medium. 1 mM IPTG was added to media 
to derepress the Iac or tat promoters when ap- 
propriate. Plasmid pDR540 was purchased from 
PL-Pharmacia, Uppsala, and plasmid pUR291 
was obtained from U. Ruther. 
Lysozyme was from Sigma (St. Louis, MO). 
Restriction endonucleases were from Boehringer 
(Mannheim), BRL (Gaithesburg, MD) or New 
England Biolabs (Beverly, MA); T4 ligase and all 
other enzymes were from Boehringer. All en- 
zymatic reactions were performed according to the 
supplier’s instructions unless otherwise specified. 
Sequencing by partial chemical degradation was 
performed according to Maxam and Gilbert [6]. 
The fused&galactosidase-apoA1 protein was ex- 
tracted from bacterial cultures according to 
previous methods for ,&galactosidase [7]. An 
enzyme-linked immunoasssay for apoA1 was 
developed according to standard methods [S]. 
3. RESULTS AND DISCUSSION 
3.1. Reconstruction of the coding sequence for 
mature apoAI 
A full-length cDNA clone coding for apoA1 
(pAI/A) was obtained from a human liver cDNA 
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library [9]. This clone included coding sequences 
for the signal peptide, the propeptide and the 
whole mature protein. To express the mature pro- 
tein in E. coli, we needed to reconstruct its 5 ’ -end 
to remove the unwanted sequences and let the 
apoA1 gene begin after the ATG start codon. For 
this purpose, the EcoRI-BumHI fragment contain- 
ing the apoA1 gene was purified from plasmid 
pAI/A, restricted with Sau3AI under partial diges- 
tion conditions, and ligated to a synthetic adapter 
as described in fig.1. Thus reconstructed, the 
5 ’ -end of the apoA1 gene was preceded by an ATG 
start codon and a BumHI cohesive end, allowing 
insertion into the BarnHI site of plasmid 
pAT153PvuII8 [9]. The resulting construction, 
with the correct orientation of the adapter, was 
designated pAI/12. By this strategy, the mature 
apoA1 coding sequence could be moved to any ex- 
pression vector carrying a BarnHI site after a 
Shine-Dalgarno sequence. 
3.2. Expression in pDR540 
In a first attempt to express this gene in E. coli, 
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Fig.1. Reconstruction f the 5’-end of the gene coding 
for mature apoAI. A 890 bp EcoRI-BumHI fragment 
was isolated from plasmid pAI/A, subjected to partial 
Suu3AI digestion, and the fragment containing the 
mature apoA1 coding region starting at the first Sau3AI 
residue was ligated to a synthetic oligonucleotide adapter 
assembled by annealing and ligating the single-stranded 
precursors l-4. The resulting 790 bp fragment had 
cohesive BumHI extremities, and was ligated to BarnHI- 
linearized pATl53-PvuII8 yielding plasmid pAI/ as 
b 
Fig.2. Construction of apoA1 expression plasmids. The 
apoA1 fragment was recovered from pAI/l2, ligated to 
BarnHI-linearized pDR540 or pUR291, and the correct 
orientation of the insert was verified by cutting 
transformants with Hind111 and XhoI. The boundary 
region between each plasmid and the beginning of the 
reconstructed apoA1 gene are illustrated. In pRL67, 
upper-case amino acid residues are those of ,8- 
galactosidase and apoA1, while lower-case residues 
derive from the insertion of the reconstructed apoA1 
described in the text. gene at the BumHI site of pUR291. 
we employed plasmid pDR540 which contains a tat 
promoter, the lac operator region and Shine- 
Dalgarno sequence followed by a BarnHI cloning 
site and, further downstream, the GalK gene [lo]. 
The apoA1 gene was excised by BarnHI digestion 
of pAI/ and inserted into BamHI-linearized 
pDR540. The recombinant expression plasmid was 
designated pLS59 (fig.2a). 
Attempts to detect apoA1 production in extracts 
of pLS59 by enzyme-linked immunoassay or im- 
munoblotting were unsuccessful. These negative 
results might be due to a transcriptional and/or to 
a translational blockade in the apoA1 gene, or to 
rapid degradation of apoA1 inside the bacterial 
cell. In this recombinant, a polycistronic mRNA 
should result from the fusion of apoA1 mRNA to 
GalK mRNA from pDR540. Production of GalK 
was monitored in parallel in cells harboring 
pDR540 or pLS59 to verify the presence of the 
fused mRNA. No significant differences in GalK 
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levels were observed between the 2 plasmids (not 
shown), supporting the hypothesis that expression 
of the apoA1 gene was prevented at the post- 
transcriptional evel. 
3.3. Expression in pUR291 
To overcome these problems, we constructed a 
fusion recombinant between the gene coding for P- 
galactosidase and the modified apoA1 gene. luc fu- 
sions were recently described as able to achieve ex- 
pression of otherwise highly labile proteins [ 111. 
The BarnHI fragment containing the modified 
apoA1 gene described in fig.1 was inserted in 
BarnHI-linearized pUR291 [12] and the correctly 
oriented recombinant plasmid was designated 
pRL67. The resulting in-frame fusion boundary 
region is detailed in fig.2b. Production of the fu- 
sion protein by pRL67 was monitored by SDS- 
polyacrylamide gel electrophoresis of extracts 
from IPTG-induced cultures carrying pUR291 or 
pRL67. As expected, a prominent p-galactosidase 
band was present in the extract from induced 
cultures harboring pUR291. Two major bands 
were present in the extract harboring pRL67: one 
migrated correspondingly to the predicted 
molecular mass of the fused protein (144 kDa), the 
other migrated at approximately the same 
molecular mass of the ,&galactosidase band of 
pUR291 (fig.3, lanes 2 and 3). ApoAI cross- 
reactivity was observed in the fused product by im- 
munoblot analysis. The 144 kDa band was the 
only band recognized by an anti-apoA1 antiserum 
in an extract from cells harboring plasmid pRL67 
(fig.3, lane 5). Neither the major lower band nor 
any other protein of lower molecular mass was 
recognized by the anti-apoA1 antiserum. 
A partial degradation product comigrating with 
,&-galactosidase in SDS-polyacrylamide gels was 
also observed by others in a lysozyme-P- 
galactosidase fusion [12]. Since the major lower 
band that we observed could arise from degrada- 
tion of the fused product, a pulse-chase xperiment 
with labelled methionine was performed in cells 
harboring pRL67. After either a 2 min or 5 min 
pulse, only the 144 kDa band was labelled with 
[35S]methionine. Adding excess unlabelled methio- 
nine resulted in fading and disappearance of the 
144 kDa band, while other bands of lower 
molecular mass eventually appeared with longer 
chase times in the region between the 144 kDa 
Fig.3. Immunoblot analysis of pUR291 and pRL67. 
Aliquots of bacterial cultures were centrifuged and 
resuspended in loading buffer (62.5 mM Tris-Cl, pH 
6.8, 10% glycerol, 5% 2-mercaptoethanol, 5% SDS, 
0.0025% bromophenol blue). Aliquots were boiled and 
electrophoresed in duplicate on a 7.5% SDS- 
polyacrylamide slab gel which was then stained with 
Coomassie blue. One half of the gel was stained with 
Coomassie blue (lanes l-3), the other (lanes 4-5) was 
subjected to electroblotting on a nitrocellulose filter. 
The filter was incubated with purified rabbit anti-human 
apoA1 antiserum and with protein A-horseradish 
peroxidase conjugate. Lanes: 1 M, standards: myosin 
H-chain (200000), phosphory ase I b (97400), BSA 
(68000) and ovalbumin (43000); 2and 4, IPTG-induced 
cultures containing pUR291; 3 and 5, IPTG-induced 
cultures containing pRL67. 
band and P-galactosidase (fig.4). These results, 
together with those of the immunoblot analysis, in- 
dicated that degradation was presumably confined 
to the apoA1 moiety of the fusion product, and 
that it occurred inside the cell with an approximate 
half-life of about 45 min. 
Extracts from IPTG-induced and uninduced 
cultures harboring pUR291 and pRL67 were also 
tested using an enzyme-linked immunoassay for 
apoA1. Induced cultures harboring pRL67 were 
positive for apoA1 cross-reactivity, with levels of 
about 5 pg/ml of bacterial culture. 
In conclusion, it seems that one way to obtain 
expression of human apoA1 in E. coli is to fuse it 
to a large and stable protein such as ,& 
galactosidase. The fusion product should con- 
345 
Volume 194, number 2 FEBS LETTERS January 1986 
Fig.4. Pulse-chase analysis of pRL67. Cells harboring pRL67 were grown in M9+ IPTG, pulsed for 2 or 5 min with 
[35S]methionine, and chased with a 20000-fold excess of unlabeiled methionine. Aliquots were withdrawn at 5, IS, 30, 
60 and 120 min, quickly frozen, thawed and trichloroacetic acid precipitated. Centrifuged pellets were resuspended in 
loading buffer as described in fig.3 and electrophoresed on a 7.5% SDS-polyacrylamide slab gel. The gel was soaked 
in EnHance (New England Nuclear) for 60 min, dried and exposed on a Fuji RX film for 2 days. Lanes: l-6, 2 min 
pulse; 7-12, 5 min pulse; 1 and 7, no chase. Chase times: lanes 2 and 8, 5 min; lanes 3 and 9, 15 min; lanes 4 and 10, 
30 min; lanes 5 and 11, 1 h; lanes 6 and 12, 2 h. Lane 13, pUR291, 5 min pulse, no chase. 116K, 116 kDa p7- 
galactosidase; 144 Kd, 144 kDa fused fi-galactosidase-apoA1. 
stitute a useful tool by itself, being labelled by fi- 
galactosidase. Inserting the recognition site for a 
specific protease should enable the cleavage of the 
apoA1 moiety from its fused ~-galactosidase 
counterpart, to obtain the recombinant apo- 
lipoprotein in purified form. Expression of human 
apoA1 in E. coli will enable us to study the rela- 
tionships between structure and biological activity 
by obtaining specific mutations, using well 
established site-directed mutagenesis techniques, 
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